Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-17 DOI:10.1080/14737167.2025.2521444

Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao

{"title":"Cost-effectiveness analysis of sotorasib plus panitumumab in the treatment of refractory colorectal cancer with mutated KRAS G12C in the USA.","authors":"Tong Liu, Yao Yao, Xue Teng, Zhiqiang Tong, Mei Dong, Ruihong Yao","doi":"10.1080/14737167.2025.2521444","DOIUrl":null,"url":null,"abstract":"Background: This study evaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standard care in the treatment of refractory colorectal cancer (CRC) with mutated KRASG12Cfrom the perspective of healthcare payers in the U.S.A.Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of sotorasib plus panitumumab versus standard care. TheKaplan-Meier curves for overall survival (OS) and progression-free survival(PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.Results: The estimated cost for sotorasib plus panitumumab treatment was higher than that of standard care treatment (77,087.936 USD vs 8905.065 USD). In addition, the estimated utility was relatively augmented than that of standard care treatment (0.876 QALYs vs 0.857 QALYs). The ICER was calculated at 3,551,555554USD/ QALY, suggesting the sotorasib plus panitumumab therapy did not demonstrate an economic advantage over standard care therapy for refractory CRC patients with mutated KRASG12C at the threshold of 150,000 USD/ QALY.Conclusions: Sotorasib plus panitumumab did not demonstrate an economic advantage compared to standard care in the treatment of refractory CRC with mutated KRASG12C in the U.S.A.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2521444","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study evaluates the cost-effectiveness of sotorasib plus panitumumab in contrast to standard care in the treatment of refractory colorectal cancer (CRC) with mutated KRAS^G12Cfrom the perspective of healthcare payers in the U.S.A.

Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of sotorasib plus panitumumab versus standard care. TheKaplan-Meier curves for overall survival (OS) and progression-free survival(PFS) from a clinical trial were digitally extracted, and the Log-Logistic model was employed at the end of the trial to extrapolate the long-term survivals.

Results: The estimated cost for sotorasib plus panitumumab treatment was higher than that of standard care treatment (77,087.936 USD vs 8905.065 USD). In addition, the estimated utility was relatively augmented than that of standard care treatment (0.876 QALYs vs 0.857 QALYs). The ICER was calculated at 3,551,555554USD/ QALY, suggesting the sotorasib plus panitumumab therapy did not demonstrate an economic advantage over standard care therapy for refractory CRC patients with mutated KRAS^G12C at the threshold of 150,000 USD/ QALY.

Conclusions: Sotorasib plus panitumumab did not demonstrate an economic advantage compared to standard care in the treatment of refractory CRC with mutated KRAS^G12C in the U.S.A.

查看原文本刊更多论文

sotorasib联合帕尼单抗治疗美国KRAS G12C突变的难治性结直肠癌的成本-效果分析

背景：本研究从美国医疗保健支付款人的角度评估了sotorasib +帕尼单抗与标准治疗相比治疗难治性结直肠癌（CRC）突变krasg12c的成本-效果。研究设计和方法：利用3状态分割生存模型的经济评估评估了sotorasib +帕尼单抗与标准治疗的成本-效果。从临床试验中提取总生存期（OS）和无进展生存期（PFS）的kaplan - meier曲线，并在试验结束时采用Log-Logisticmodel来推断长期生存期。结果：sotorasib + panitumumab治疗的估计成本高于标准护理治疗（77,087.936美元vs 8905.065美元）。此外，与标准护理治疗相比，估计效用相对增加（0.876 QALYs vs 0.857 QALYs）。ICER的计算值为3,551,555554美元/ QALY，表明对于KRASG12C突变的难治性CRC患者，在150,000美元/ QALY的阈值下，sotorasib +帕尼单抗治疗没有表现出比标准护理治疗的经济优势。结论：在美国，与标准治疗相比，Sotorasib + panitumumab在治疗难治性CRC突变KRASG12C方面没有表现出经济优势

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.